|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Margulis V, Youssef RF, Karakiewicz PI, et
al; Upper Tract Urothelial Carcinoma Group. Preoperative
multivariable prognostic model for prediction of nonorgan confined
urothelial carcinoma of the upper urinary tract. J Urol.
184:453–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oosterlinck W, Solsona E, van der Meijden
AP, et al; European Association of Urology. EAU guidelines on
diagnosis and treatment of upper urinary tract transitional cell
carcinoma. Eur Urol. 46:147–154. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raman JD and Scherr DS: Management of
patients with upper urinary tract transitional cell carcinoma. Nat
Clin Pract Urol. 4:432–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hall MC, Womack S, Sagalowsky AI, Carmody
T, Erickstad MD and Roehrborn CG: Prognostic factors, recurrence,
and survival in transitional cell carcinoma of the upper urinary
tract: a 30-year experience in 252 patients. Urology. 52:594–601.
1998.PubMed/NCBI
|
|
6
|
Langner C, Hutterer G, Chromecki T,
Winkelmayer I, Rehak P and Zigeuner R: pT classification, grade,
and vascular invasion as prognostic indicators in urothelial
carcinoma of the upper urinary tract. Mod Pathol. 19:272–279. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Novara G, De Marco V, Gottardo F, et al:
Independent predictors of cancer-specific survival in transitional
cell carcinoma of the upper urinary tract: multi-institutional
dataset from 3 European centers. Cancer. 110:1715–1722. 2007.
View Article : Google Scholar
|
|
8
|
Secin FP, Koppie TM, Salamanca JI, et al:
Evaluation of regional lymph node dissection in patients with upper
urinary tract urothelial cancer. Int J Urol. 14:26–32. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brown GA, Busby JE, Wood CG, et al:
Nephroureterectomy for treating upper urinary tract transitional
cell carcinoma: Time to change the treatment paradigm? BJU Int.
98:1176–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Waldert M, Karakiewicz PI, Raman JD, et
al: A delay in radical nephroureterectomy can lead to upstaging.
BJU Int. 105:812–817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zigeuner R, Shariat SF, Margulis V, et al:
Tumour necrosis is an indicator of aggressive biology in patients
with urothelial carcinoma of the upper urinary tract. Eur Urol.
57:575–581. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Margulis V, Shariat SF, Matin SF, et al;
The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of
radical nephroureterectomy: a series from the Upper Tract
Urothelial Carcinoma Collaboration. Cancer. 115:1224–1233. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Epstein JI, Amin MB, Reuter VR and Mostofi
FK: The World Health Organization/International Society of
Urological Pathology consensus classification of urothelial
(transitional cell) neoplasms of the urinary bladder. Bladder
Consensus Conference Committee. Am J Surg Pathol. 22:1435–1448.
1998. View Article : Google Scholar
|
|
14
|
Eng MK and Shalhav AL: Laparoscopic
nephroureterectomy: long-term outcomes. Curr Opin Urol. 18:157–162.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kikuchi E, Margulis V, Karakiewicz PI, et
al: Lymphovascular invasion predicts clinical outcomes in patients
with node-negative upper tract urothelial carcinoma. J Clin Oncol.
27:612–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Remzi M, Haitel A, Margulis V, et al:
Tumour architecture is an independent predictor of outcomes after
nephroureterectomy: a multi-institutional analysis of 1363
patients. BJU Int. 103:307–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Otto W, Shariat SF, Fritsche HM, et al:
Concomitant carcinoma in situ as an independent prognostic
parameter for recurrence and survival in upper tract urothelial
carcinoma: a multicenter analysis of 772 patients. World J Urol.
29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koda S, Mita K, Shigeta M and Usui T: Risk
factors for intravesical recurrence following urothelial carcinoma
of the upper urinary tract: no relationship to the mode of surgery.
Jpn J Clin Oncol. 37:296–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kusuda Y, Miyake H, Terakawa T, Kondo Y,
Miura T and Fujisawa M: Gender as a significant predictor of
intravesical recurrence in patients with urothelial carcinoma of
the upper urinary tract following nephroureterectomy. Urol Oncol.
Aug 6–2011.(Epub ahead of print).
|
|
20
|
Terakawa T, Miyake H, Muramaki M, Takenaka
A, Hara I and Fujisawa M: Risk factors for intravesical recurrence
after surgical management of transitional cell carcinoma of the
upper urinary tract. Urology. 71:123–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pieras E, Frontera G, Ruiz X, Vicens A,
Ozonas M and Pizá P: Concomitant carcinoma in situ and tumour size
are prognostic factors for bladder recurrence after
nephroureterectomy for upper tract transitional cell carcinoma. BJU
Int. 106:1319–1323. 2010. View Article : Google Scholar
|
|
22
|
Wu WJ, Ke HL, Yang YH, Li CC, Chou YH and
Huang CH: Should patients with primary upper urinary tract cancer
receive prophylactic intravesical chemotherapy after
nephroureterectomy? J Urol. 183:56–61. 2010. View Article : Google Scholar
|
|
23
|
Novara G, De Marco V, Dalpiaz O, et al:
Independent predictors of contralateral metachronous upper urinary
tract transitional cell carcinoma after nephroureterectomy:
multi-institutional dataset from three European centers. Int J
Urol. 16:187–191. 2009. View Article : Google Scholar
|
|
24
|
Youssef RF, Shariat SF, Lotan Y, et al:
Prognostic effect of urinary bladder carcinoma in situ on clinical
outcome of subsequent upper tract urothelial carcinoma. Urology.
77:861–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Remzi M, Shariat S, Huebner W, Fajkovic H
and Seitz C: Upper urinary tract urothelial carcinoma: what have we
learned in the last 4 years? Ther Adv Urol. 3:69–80.
2011.PubMed/NCBI
|
|
26
|
Lehmann J, Suttmann H, Albers P, et al:
Surgery for metastatic urothelial carcinoma with curative intent:
the German experience (AUO AB 30/05). Eur Urol. 55:1293–1299. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bolenz C, Shariat SF, Fernández MI, et al:
Risk stratification of patients with nodal involvement in upper
tract urothelial carcinoma: value of lymph-node density. BJU Int.
103:302–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abe T, Shinohara N, Muranaka M, et al:
Role of lymph node dissection in the treatment of urothelial
carcinoma of the upper urinary tract: multi-institutional relapse
analysis and immunohistochemical re-evaluation of negative lymph
nodes. Eur J Surg Oncol. 36:1085–1091. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lughezzani G, Jeldres C, Isbarn H, et al:
A critical appraisal of the value of lymph node dissection at
nephroureterectomy for upper tract urothelial carcinoma. Urology.
75:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roscigno M, Shariat SF, Margulis V, et al:
Impact of lymph node dissection on cancer specific survival in
patients with upper tract urothelial carcinoma treated with radical
nephroureterectomy. J Urol. 181:2482–2489. 2009. View Article : Google Scholar : PubMed/NCBI
|
